Company Filing History:
Years Active: 2025
Title: **Michael Bazelot: Innovator in Cannabidiol Research**
Introduction
Michael Bazelot is an inventive mind located in Cambridge, GB, known for his significant contributions to the field of medical research, particularly in the treatment of tuberous sclerosis complex (TSC). With one patent to his name, Bazelot's work focuses on utilizing cannabidiol (CBD) for therapeutic purposes.
Latest Patents
Bazelot's patent, titled "Use of cannabidiol in the treatment of tuberous sclerosis complex," explores the application of CBD for mitigating tumors associated with TSC. The invention highlights that CBD has demonstrated the ability to decrease both the number and size of marker cells, namely pS6, in a zebrafish model of TSC. This suggests a potential disease-modifying effect, wherein treatment with CBD may lead to a reduction or even prevention of the benign tumors that TSC patients often experience. The patent emphasizes the use of a highly purified extract of cannabis with CBD content exceeding 98%, while maintaining low levels of other cannabinoids such as tetrahydrocannabinol (THC), ensuring it does not exceed 0.15%. Furthermore, the CBD can also be synthetically produced and may be used in conjunction with other TSC treatments, such as rapamycin and everolimus.
Career Highlights
Michael Bazelot is associated with Jazz Pharmaceuticals Research UK Limited, a company dedicated to developing innovative medicines for serious diseases. His work contributes significantly to both the academic community and the pharmaceutical industry, pushing forward the boundaries of treatment options for individuals affected by TSC.
Collaborations
Bazelot has collaborated with esteemed colleagues, including Benjamin Whalley and William Hind, who share a passion for advancing research in cannabinoid applications and improving therapeutic responses for patients suffering from various conditions, including TSC.
Conclusion
In conclusion, Michael Bazelot stands out as a prominent inventor in the field of cannabidiol research, with a focus on innovative treatments for tuberous sclerosis complex. His patent not only marks a pivotal moment in medical advancements but also indicates the growing importance of cannabinoid studies in contemporary medicine. As research continues, Bazelot's contributions will undoubtedly impact the future of therapeutic strategies for TSC and beyond.